Several studies have looked at the risks and benefits associated with the use of dexmedetomidine, an alpha-2 agonist
, for postoperative pain.
23) The combination of an alpha-2 agonist
and local anesthetic agent was also shown to produce longer-lasting analgesia.
The alpha-2 agonist
clonidine (6) may be used to relieve adrenergic withdrawal symptoms.
The alpha-2 agonist
lofexidine, used with methadone for opioid detoxification, induced QT prolongation in a subject enrolled in a study of the safety of the drug as a daily therapy, reported John Schmittner, M.
However, due to severe side effects like muscle rigidity, frequent convulsions, and rough recoveries, these agents should only be used in combination with an alpha-2 agonist
or another tranquilizing or sedative drug (Kreeger et al.
ALPHAGAN(tm) is a selective alpha-2 agonist
which significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters.
Maldonado and his colleagues use a nonbenzodiazepine withdrawal protocol based on the alpha-2 agonist
clonidine because alpha-2 blockers address the norepinephrine overload that drives 85% of the withdrawal symptoms.
s alpha-2 agonist
Precedex (dexmedetomidine hydrochloride) for intravenous sedation provides comparable effectiveness to commonly used gamma-aminobutyric acid (GABA)-agonist midazolam for greater-than-24-hour sedation of mechanically ventilated patients in the intensive care unit (ICU).
MedPredict's panelists predict successes and failures in a number of therapeutic targets, including mu receptor agonists/opioids, serotonergic/noradrenergics, sodium and calcium channel blockers, NMDA/glutamate, Alpha-2 agonist
, (mGlu2/3), acetylcholine, AMPA, cannabinoid, NF Kappa b, TRPV1/vanilloids, stimulants, NSAIDs, hyaluronic acid, anti-IL-10 and anti-IL-1.
8 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) today announced regulatory filings with United States and European health authorities seeking approval for dexmedetomidine, an alpha-2 agonist
, a sedative with analgesic properties for use in patients in an intensive care setting.
Although further analyses revealed that these concerns were unfounded, clinicians have continued to question the milder cardiovascular effects of stimulants for ADHD, as well as the effects of combining stimulants with alpha-2 agonists
such as guanfacine, which can improve cognitive function in ADHD, he said.
Since then, the pharmaceutical industry has introduced topical carbonic anhydrase inhibitors (Trnsopt), alpha-2 agonists
(Iopidine) and, best of all, prostaglandin analogues (Xalatan), followed by combination drugs and other rival branded preparations in these three new categories.